Thermo Fisher Scientific has introduced PharmacoScan, a microarray-based research tool that contains pharmacogenomic content with relevant markers involved in absorption, distribution, metabolism and excretion (ADME) pathways of commonly prescribed medicines.
Using PharmacoScan, researchers can interrogate more than 4,600 markers in nearly 1,200 genes involved in pharmacogenomics pathways with a single assay. The solution is enabled by the Axiom genotyping solution and automated GeneTitan multi-channel array plate processing instrument, and enables lot-to-lot reproducibility and data consistency and high-throughput and affordable sample processing, a key factor for multi-year pharmacogenomics profiling of prospective cohorts.
The solution was developed in collaboration with experts in the field and leading PGx consortia, such as the Clinical Pharmacogenetics Implementation Consortium, PharmaADME, and PharmGKB. Early-access customers include the University of Montreal Hospital Research Centre; University of Alberta; and leading genomic service laboratories, including RUCDR Infinite Biologics and Eurofins Genomics/AROS Applied Biotechnology, Thermo Fisher said.